Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$83.90M+763.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chad Robins
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 624
- Beta
- 2.15
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.26
Financials
Revenue
$83.90M+763.6%Net Income
$2.88MEBITDA
$3.15MFree Cash Flow
$7.68MEPS (diluted)
$0.02Shares Outstanding (diluted)
186.88M+76.5%Operating Expenses
$64.00MCash & Debt
$298.95MReturn of Capital
$0.00Revenue by Segment (annual)
$154.34MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $276.98M | $-59.50M | $-0.39 |
| 2024 | $178.96M | $-159.49M | $-1.08 |
| 2023 | $170.28M | $-225.25M | $-1.56 |
| 2022 | $185.31M | $-200.19M | $-1.40 |
| 2021 | $154.34M | $-207.28M | $-1.46 |
| 2020 | $98.38M | $-146.23M | $-1.06 |
| 2019 | $85.07M | $-68.61M | $-0.47 |
| 2018 | $55.66M | $-46.45M | $-0.44 |
| 2017 | $38.45M | $-42.83M | $-0.41 |
Valuation
ADPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57-19.05%Social Signal Score
Mentions (22)
- News (RSS)investing·2d ago·Neutral
Cathie Wood’s ARK buys Anthropic stock, sells Nvidia and Adaptive Bio
View source ↗ - News (RSS)techcrunch·4d ago·Neutral
Sony’s updated turntable is an easy entry into the world of vinyl Sony's updated turntable for beginners features automatic playback, USB connectivity, and aptX Adaptive Bluetooth.
View source ↗ - Newszacks.com·12d ago·Positive
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - News (RSS)investing·13d ago·Neutral
Adaptive Biotechnologies stock hits 52-week high at 30.74 USD
View source ↗ - News (RSS)fool·17d ago·Positive
Adaptive (ADPT) Q3 2026 Earnings Call Transcript Total company profitability arrived early as MRD guidance moved higher.
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Neutral
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.
View source ↗ - Newszacks.com·18d ago·Neutral
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·18d ago·Negative
Adaptive Biotechnologies Q3 Earnings Call Highlights Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Global Oncology Clinical Trials Market Size, Share, Trends, and Forecast, 2026-2033 | AI, Precision Medicine, and Adaptive Trials Drive 7.9% CAGR to USD 58.9 Billion Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Oncology Clinical Trials Market Size, Share and Trends Analysis Report by Phase Type, Study Design, Indication, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets. com's offering. The global oncology clinical trials market was valued at an estimated USD 32.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
…l ASP up 7% and test volumes up 43%, driving adjusted EBITDA margin to 14%. Elimination of the OrbiMed revenue share and a $345M zero-coupon note refinancing provide ADPT with over five years of runway and remove a major growth tax.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
System Integration - Global Strategic Business Report: Capitalize on the $1.1 Trillion Shift by 2032 as Aaeon Technology, 3C System, A C S, and Adaptive Recognition Accelerate Disruption Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "System Integration - Global Strategic Business Report" has been added to ResearchAndMarkets. com's offering. The global system integration market was valued at an estimated US$427. 1 billion in 2025 and is projected to reach US$1.
View source ↗ - News (RSS)zerohedge·49d ago·Neutral
California Attorney General Subpoenas OpenAI In Cybersecurity Inquiry California Attorney General Subpoenas OpenAI In Cybersecurity Inquiry Authored by Kimberly Hayek via The Epoch Times, California Attorney General Rob Bonta served an investigative subpoena to OpenAI on Wednesday, according to a statement released Thursday. The OpenAI logo on May 20, 2024. Dado Ruvic/Illustration/ReutersThe demand is part of the California Department of Justice's ongoing investigation into incidents arising fro
View source ↗ - Newsfeeds.newsfilecorp.com·55d ago·Negative
Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to
View source ↗ - Newsglobenewswire.com·58d ago·Neutral
…nsitive MRD Testing in New International Myeloma Society Definition of Cure SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scot…
View source ↗ - News (RSS)investing·59d ago·Neutral
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD
View source ↗ - News (RSS)yahoo·60d ago·Neutral
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
View source ↗ - Newsbusinesswire.com·61d ago·Negative
QAD | Redzone Expands ChampionAI Across Adaptive ERP with Champion Assist and New Accounts Payable Champion CHICAGO & MIAMI--(BUSINESS WIRE)--Champions of Manufacturing — QAD | Redzone, the company behind the world's number one platform for manufacturers, announced a major expansion of ChampionAI, the agentic AI engine that runs the entire QAD | Redzone platform: Champion Assist, a conversational interface inside Adaptive ERP, and the new Accounts Payable Champion, an AI agent that manages the i
View source ↗ - News (RSS)seekingalpha·67d ago·Positive
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsgeekwire.com·97d ago·Neutral
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $-0.04 per share
Typical surprise +41.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.02 vs $-0.09beat
- Wed, Jul 29$-0.25 vs $-0.13miss
- Tue, May 5$-0.13 vs $-0.16beat
- Thu, Feb 5$-0.09 vs $-0.19beat
- Thu, Nov 6$0.06 vs $-0.18beat
- Tue, Aug 5$-0.17 vs $-0.24beat
Estimates and results for ADPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADPT officers and directors.
- Bought
- —
- Sold
- $10.3m
0 trades
58 trades
- Rubinstein Juliesold
- Rubinstein Juliesold
- Rubinstein Juliesold
- Rubinstein Juliesold
- Bobulsky Susansold
- Rubinstein Juliesold
- Rubinstein Juliesold
- Rubinstein Juliesold
42 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
